
businessMay 11, 20267:13pending
Enlivex advances Allocetra while expanding into prediction markets
About this episode
Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction markets.
Hershkovitz explained that Enlivex continues progressing development of Allocetra for osteoarthritis while simultaneously gaining exposure to the growing prediction market sector through the RAIN token ecosystem.
The company completed a transformative transaction at the end of 2025 that established a treasury strategy centered around the RAIN protocol, which management describes as a decentralized prediction market platform. Enlivex invested more than $200 million in RAIN tokens and also secured an exclusive option to acquire additional tokens at a fixed price.
Hershkovitz said the structure provides shareholders with significant upside exposure tied to the future growth of the protocol and broader adoption of decentralized prediction markets.
On the clinical side, Enlivex continues advancing Allocetra™ for knee osteoarthritis. The company previously completed a Phase 2a double-blind, placebo-controlled study that demonstrated statistically significant improvements in pain reduction and functional outcomes among patients over the age of 64.
Enlivex has now received authorization from the U.S. Food and Drug Administration to begin a Phase 2b study and has also secured Clinical Trial Application approval in Denmark. Topline results from the Phase 2b trial are expected in the first half of 2027 and could support advancement into Phase 3 development.
The company believes its combination of biotechnology development and strategic exposure to emerging digital asset infrastructure creates a differentiated growth profile as both sectors continue to evolve.
#proactiveinvestors #enlivixltd #nasdaq #enlv #Biotech #Allocetra #Osteoarthritis #ClinicalTrials #PredictionMarkets #DigitalAssets #RAINToken #HealthcareInnovation
Get every episode summarized
Each time Proactive - Interviews for investors publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Proactive - Interviews for investors

Titan Minerals extends gold-silver mineralisation at Dynasty
Proactive - Interviews for investors
Sep 9, 20263:46failed

Krakatoa Resources: Zopkhito drilling extends gold-antimony potential
Proactive - Interviews for investors
Sep 9, 20264:07failed

Gaming Realms CEO: Content growth accelerating as company expands into new marke...
Proactive - Interviews for investors
Sep 9, 20262:59failed

genedrive CEO: NHS adoption and global expansion drive point-of-care testing pus...
Proactive - Interviews for investors
Sep 9, 20268:49failed